# Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis

> **NCT00464204** · PHASE3 · COMPLETED · sponsor: **Fresenius Kabi** · enrollment: 196 (actual)

## Conditions studied

- Sepsis

## Interventions

- **DRUG:** 6 % Hydroxyethylstarch 130/0.4 = "Voluven®"
- **DRUG:** 0.9 % NaCl

## Key facts

- **NCT ID:** NCT00464204
- **Lead sponsor:** Fresenius Kabi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2010-05
- **Final completion:** 2010-12
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2012-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00464204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00464204, "Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00464204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*